Retatrutide is one of the most talked-about weight loss drugs right now. It targets three hormone receptors at once, GLP-1, GIP, and glucagon, and the clinical trial results have been striking. People lost up to 24% of their body weight over 48 weeks in Phase 2 trials published in the New England Journal of Medicine in 2023.
But that does not mean it is right for everyone. Some people face real risks taking it. Others should not take it at all.
Here is a straight answer to who should avoid taking retatrutide, based on what the research and clinical data actually show.
Who Should Not Take Retatrutide?
The list of people who should avoid retatrutide is not short. This drug works on powerful hormonal pathways and it affects multiple organ systems. If you have certain conditions, the risks outweigh the benefits.
People With a Personal or Family History of Thyroid Cancer
This is the clearest contraindication. Retatrutide, like all GLP-1 receptor agonists, carries a warning about medullary thyroid carcinoma (MTC). In animal studies, GLP-1 drugs caused thyroid C-cell tumors. The FDA has not confirmed this happens in humans, but the signal is strong enough that the warning is on every drug in this class.
If you or a first-degree relative has had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), retatrutide is off the table. Full stop.
In my experience reviewing the literature on GLP-1 drugs, this is the one area where the precautionary principle applies hard. The mechanism is plausible, the animal data is consistent, and there is no reason to take the risk.
People With a History of Pancreatitis
Can People With Pancreatitis Take Retatrutide?
No. People with a history of acute or chronic pancreatitis should not take retatrutide.
GLP-1 drugs have been linked to pancreatitis. The FDA added a pancreatitis warning to semaglutide and other GLP-1 drugs years ago. Retatrutide hits the same receptor, so the same concern applies.
What I found in the Phase 2 trial data is that pancreatitis events were rare but present. The researchers excluded people with a history of pancreatitis from the trials, which tells you something. They did not want to test it in that population because the risk was considered too high.
If you have had pancreatitis before, your pancreas is already sensitized. Adding a drug that stimulates insulin secretion and affects pancreatic enzyme activity is not a smart move.
Is Retatrutide Safe During Pregnancy?
No. Retatrutide is not safe during pregnancy.
Animal studies show GLP-1 receptor agonists cause fetal harm, including reduced fetal weight and skeletal abnormalities. Retatrutide has not been tested in pregnant humans, and it will not be, because the animal data is concerning enough to make that unethical.
The recommendation from every major endocrinology body is to stop GLP-1 drugs at least two months before trying to conceive. Some guidelines say longer. The drug needs time to clear your system before pregnancy begins.
If you are breastfeeding, the same caution applies. There is no safety data for retatrutide in breastfeeding women. Until there is, the answer is no.
This is not a gray area. If you are pregnant, planning to become pregnant, or breastfeeding, who should avoid taking retatrutide includes you.
Should People With Kidney or Liver Disease Avoid Retatrutide?
This one is more nuanced, but the short answer is yes, people with significant kidney or liver disease should be very cautious and likely avoid it.
Kidney Disease
GLP-1 drugs can cause nausea, vomiting, and reduced fluid intake. In people with already compromised kidneys, dehydration from these side effects can push kidney function over the edge. Cases of acute kidney injury have been reported with semaglutide and other GLP-1 drugs in people with pre-existing kidney disease.
Retatrutide has not been studied in people with severe chronic kidney disease (CKD stages 4 and 5). The Phase 2 trials excluded people with eGFR below 30. That means there is no safety data for that population.
If you have moderate kidney disease, the conversation with your doctor needs to happen before you start. If you have severe kidney disease, the answer is almost certainly no.
Liver Disease
Retatrutide is metabolized through standard peptide pathways, not primarily through the liver. But people with severe liver disease, like decompensated cirrhosis, were excluded from trials. The drug’s effect on liver enzymes and its interaction with compromised liver function is not well understood yet.
What I saw in the available data is that retatrutide actually improved liver fat in people with metabolic dysfunction-associated steatotic liver disease (MASLD). That is a positive signal. But that is different from people with advanced liver disease or liver failure. Those people were not studied.
Can People With Type 1 Diabetes Take Retatrutide?
No, not safely without very close medical supervision, and most clinicians would say avoid it entirely for now.
Here is why. Retatrutide stimulates insulin secretion through the GLP-1 pathway. In people with type 1 diabetes, the pancreas does not produce insulin. The GLP-1 mechanism works differently in this population, and the glucagon-suppressing effect of the drug can cause dangerous hypoglycemia.
The Phase 2 trials enrolled people with type 2 diabetes, not type 1. There is no clinical trial data on retatrutide in type 1 diabetes. Using a drug with no safety data in a population with a condition that already requires precise glucose management is a serious risk.
People with type 2 diabetes who are on insulin also need to be careful. The combination of retatrutide and insulin can cause hypoglycemia. Insulin doses typically need to be reduced when starting a GLP-1 drug.
Are Children or Adolescents Advised Against Taking Retatrutide?
Yes. Retatrutide has not been studied in anyone under 18. The Phase 2 and ongoing Phase 3 trials enrolled adults only.
This is not just a regulatory technicality. Children and adolescents are still developing. Their hormonal systems, bone density, and metabolic pathways are in flux. A drug that powerfully alters GLP-1, GIP, and glucagon signaling could have effects on development that we simply do not understand yet.
Some GLP-1 drugs like semaglutide have now been approved for adolescents aged 12 and over for obesity treatment. But that approval came after specific pediatric trials. Retatrutide has not done those trials. Until it does, the answer for anyone under 18 is no.
What Other Conditions Should Make You Pause?
Gastroparesis
Retatrutide slows gastric emptying. That is part of how it reduces appetite. But if you already have gastroparesis, a condition where the stomach empties too slowly, adding a drug that slows it further can cause serious problems. Nausea, vomiting, and nutritional deficiencies become much harder to manage.
Eating Disorders
This is an area the research community is starting to pay attention to. GLP-1 drugs suppress appetite strongly. In people with a history of restrictive eating disorders like anorexia nervosa, that appetite suppression can reinforce dangerous behaviors. There is no clinical trial data here, but the clinical concern is real and growing.
Severe Gastrointestinal Disease
People with inflammatory bowel disease, Crohn’s disease, or other serious GI conditions were largely excluded from retatrutide trials. The drug’s GI side effects, nausea, vomiting, diarrhea, constipation, can be severe in the early weeks. In someone with an already inflamed or compromised gut, that is a meaningful risk.
Gallbladder Disease
Rapid weight loss increases the risk of gallstones. GLP-1 drugs have been associated with gallbladder problems including cholecystitis and cholelithiasis. If you already have gallbladder disease or a history of gallstones, this is a conversation to have with your doctor before starting.
Drug Interactions to Know About
Retatrutide slows gastric emptying, which changes how other medications are absorbed. This matters for drugs with narrow therapeutic windows.
- Oral contraceptives may be absorbed differently. Women on the pill should use backup contraception for at least four weeks after starting retatrutide.
- Thyroid medications like levothyroxine need to be taken consistently and monitored, because absorption timing can shift.
- Warfarin and other anticoagulants require closer INR monitoring when starting or stopping retatrutide.
- Insulin and sulfonylureas carry a higher hypoglycemia risk when combined with retatrutide.
FAQ
Is retatrutide approved yet?
As of 2025, retatrutide is still in Phase 3 clinical trials. It is not FDA approved. It is not available as a prescription drug through standard channels. Anyone selling it as a finished injectable product right now is operating outside of approved pharmaceutical channels.
Can healthy people with no medical conditions take retatrutide?
Even in healthy adults, retatrutide carries the thyroid cancer warning and the pancreatitis risk. No one should take it without medical supervision and a clear clinical reason. Using it purely for cosmetic weight loss without a BMI or metabolic health indication is not what the drug was designed for.
What BMI is retatrutide being studied for?
The Phase 2 trials enrolled people with a BMI of 27 or higher with at least one weight-related condition, or a BMI of 30 or higher without additional conditions. That is the population where the benefit-risk calculation makes sense based on current data.
How do I know if retatrutide is right for me?
Talk to a doctor who understands metabolic health and the GLP-1 drug class. Bring your full medical history including any thyroid conditions, GI history, kidney function, and current medications. The decision is not just about your weight. It is about your whole health picture.
The Bottom Line
Retatrutide shows real promise for weight loss and metabolic health. The Phase 2 data is some of the strongest we have seen in this space. But the drug is not for everyone, and the list of people who should avoid it is meaningful.
Pregnant women, people with thyroid cancer history, pancreatitis history, severe kidney or liver disease, type 1 diabetes, and anyone under 18 should not take it. People with gastroparesis, eating disorders, serious GI disease, or gallbladder problems need to approach it with serious caution.
If you are working on your weight and metabolic health and want to understand what tools, including pharmaceutical ones, might fit your situation, working with a qualified online personal trainer who understands the full picture of nutrition, training, and medical context can help you make smarter decisions. You can explore that kind of support at Fitness Network.
The drug is a tool. Like any tool, it only makes sense in the right hands for the right job.
